Royal Bank of Canada Has $30.52 Million Position in DaVita Inc. (NYSE:DVA)

Royal Bank of Canada decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 26.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 204,056 shares of the company's stock after selling 73,533 shares during the quarter. Royal Bank of Canada owned about 0.25% of DaVita worth $30,516,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. United Capital Financial Advisors LLC lifted its holdings in DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after purchasing an additional 62 shares during the period. Freedom Investment Management Inc. increased its holdings in shares of DaVita by 3.6% in the 4th quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after purchasing an additional 62 shares during the period. Exchange Traded Concepts LLC increased its holdings in shares of DaVita by 8.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after purchasing an additional 68 shares during the period. Impact Partnership Wealth LLC increased its holdings in shares of DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after purchasing an additional 70 shares during the period. Finally, Nilsine Partners LLC increased its holdings in shares of DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after purchasing an additional 92 shares during the period. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

DaVita stock traded up $1.63 during trading hours on Tuesday, reaching $139.82. 794,960 shares of the company were exchanged, compared to its average volume of 826,146. The firm has a market cap of $10.56 billion, a price-to-earnings ratio of 13.02, a PEG ratio of 1.07 and a beta of 1.14. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a 50-day moving average of $145.09 and a 200 day moving average of $153.34. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the prior year, the business earned $2.26 earnings per share. The company's revenue was up 5.0% on a year-over-year basis. As a group, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DVA. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Truist Financial lowered their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.